INTRODUCTION OF A LOW-DOSE LEVONORGESTREL INTRAUTERINE CONTRACEPTIVE SYSTEM: A THREE-YEAR BUDGET IMPACT ANALYSIS FROM A THIRD-PARTY PAYER PERSPECTIVE IN THE UNITED STATES

被引：0
|
作者：
Trussell, J. [1 ]
Ferrufino, C. P. [2 ]
Hawes, C. [3 ]
Pocoski, J. [4 ]
Filonenko, A. [5 ]
Kim, R. S. [4 ]
McCoy, M. A. [4 ]
Law, A. W. [4 ]
机构：
[1] Princeton Univ, Princeton, NJ 08544 USA
[2] IMS Hlth, Alexandria, VA USA
[3] IMS Hlth, London, England
[4] Bayer HealthCare Pharmaceut Inc, Wayne, NJ USA
[5] Bayer Pharma AG, Berlin, Germany
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.320
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A71 / A72
页数：2
相关论文
共 13 条
  • [1] BUDGET IMPACT ANALYSIS OF INTRODUCTION OF BEVACIZUMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE
    Ektare, V
    Liu, R.
    Stephens, J.
    Shelbaya, A.
    Yang, J.
    VALUE IN HEALTH, 2020, 23 : S15 - S15
  • [2] BUDGET IMPACT ANALYSIS OF INTRODUCTION OF RITUXIMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE
    Ektare, V
    Liu, R.
    Stephens, J.
    Al Taie, A.
    Shelbaya, A.
    VALUE IN HEALTH, 2020, 23 : S16 - S17
  • [3] Cost-effectiveness analysis of a low-dose contraceptive levonorgestrel intrauterine system in Sweden
    Henry, Nathaniel
    Hawes, Charlie
    Lowin, Julia
    Lekander, Ingrid
    Filonenko, Anna
    Kallner, Helena K.
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2015, 94 (08) : 884 - 890
  • [4] Dosing Patterns for Duloxetine and Predictors of High-Dose Prescriptions in Patients With Major Depressive Disorder: Analysis from a United States Third-Party Payer Perspective
    Liu, Xianchen
    Cui, Zhanglin
    Niu, Liyuan
    Faries, Douglas E.
    Ball, Tamara
    Johnstone, Bryan
    CLINICAL THERAPEUTICS, 2011, 33 (11) : 1726 - 1738
  • [5] Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspective
    Lubinga, Solomon J.
    Walder, Lydia
    Burton, Mark
    Shen, Qin
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1212 - 1221
  • [6] Cost-utility and budget impact analysis of CPAP therapy compared to no treatment in the management of moderate to severe obstructive sleep apnea in Colombia from a third-party payer perspective
    Robles, Antonio
    Gil-Rojas, Yaneth
    Amaya, Devi
    Hernandez, Fabian
    Escobar-Cordoba, Franklin
    Venegas, Marco
    Amado, Steve
    Restrepo-Gualteros, Sonia
    Echeverry, Jorge
    Marin, Fernando
    Zabala, Sandra
    Angelica Bazurto-Zapata, Maria
    Deger, Melike
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (04) : 399 - 407
  • [7] BUDGET IMPACT ANALYSIS OF INTRODUCING FRUQUINTINIB FOR THE TREATMENT OF PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER IN THE UNITED STATES FROM THE PAYER PERSPECTIVE
    Hernandez, L. G.
    Paly, V
    Li, S.
    Khanduri, P.
    Asfaw, A. A.
    Zou, D.
    VALUE IN HEALTH, 2024, 27 (06) : S106 - S106
  • [8] BUDGET IMPACT ANALYSIS OF ZANUBRUTINIB FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY FROM THE PAYER PERSPECTIVE IN THE UNITED STATES
    Liu, R.
    Yeh, Y. C.
    Yang, K.
    Gao, X.
    Balk, M.
    Tang, B.
    VALUE IN HEALTH, 2020, 23 : S434 - S434
  • [9] BUDGET-IMPACT ANALYSIS (BIA) OF THE INTRODUCTION OF 52MG LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) AS A CONTRACEPTIVE METHOD OPTION IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS) TO AVOID UNINTENDED PREGNANCY (UP) IN 15 TO 19 YEAR-OLD ADOLESCENTS
    Ramos, N. B.
    Honda, A.
    Sakagute, M.
    Nakada, C.
    Tobaruella, F.
    VALUE IN HEALTH, 2016, 19 (07) : A401 - A401
  • [10] Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the United States from the payer perspective
    Paly, Victoria Federico
    Li, Shujun
    Khanduri, Pratishtha
    Asfaw, Alemseged Ayele
    Zou, Denise
    Hernandez, Luis
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1076 - 1085
12